Research · 9 min read
What Arrives in the Box: Vials, Labels, and the Cold Chain
The form a medication ships in changes the routine, the equipment and the questions. Two orders at similar headline prices can arrive as very different objects, and the box is where you find out which one you bought.
Key takeaways
- A prefilled pen and a vial you draw from are different purchases, and the form is rarely stated on a pricing page.
- FDA says injectable GLP-1 drugs require refrigeration per their package inserts and recommends not using one that arrives warm or under-refrigerated.
- FDA generally recommends discarding a multiple-dose sterile vial within twenty-eight days of first use, even if medication remains.
- FDA has received adverse event reports that may relate to dosing errors with compounded injectable semaglutide, including patients measuring incorrectly.
- FDA has reported fraudulent labels, so the pharmacy name on a box is a claim to check against a state license database.
- Confirm before enrolling what ships with the medication, since syringes, needles and a sharps container are either included or your errand.
Answer first: the form is part of what you bought
A prefilled pen and a vial you draw from are not the same purchase. They differ in what you handle, what equipment you need, how long the container stays in use, and how much room there is for a mistake.
That difference rarely appears on a pricing page, and it is one of the more consequential things a headline figure leaves out. Ask what form the product ships in before you enroll, not after it lands.
Ask what ships alongside it too. Syringes, needles, alcohol swabs and a sharps container are either included or they are your errand, and programs differ.
Everything below is about receiving and inspecting a shipment. How to use what is inside it is written in the instructions that came with your product, and the questions belong with your prescriber or the pharmacy that prepared it.
Temperature is the first thing to check
FDA states that injectable GLP-1 drugs require refrigeration as indicated in their package inserts. That makes the cold chain part of the product rather than part of the packaging.
The agency also says it has received complaints that certain compounded GLP-1 drugs arrived warm, or with inadequate ice packs to keep the drug at recommended storage temperatures.
FDA's recommendation on that is specific: do not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, because it can affect the drug's quality.
Open the box where you can act on what you find. Note the state of the ice packs and the temperature of the vials or pens before anything goes into a refrigerator, because once it is cold you cannot tell how it arrived.
A vial holding several doses is a different object
FDA says it is aware that compounded GLP-1 medications may be dispensed in vials containing multiple doses for a patient to self-administer. That is a container you keep going back to, which introduces a clock a single-use presentation does not have.
FDA's general recommendation is that vials containing multiple doses of sterile medications be used within twenty-eight days after first use, because the risk of contamination increases after that.
The agency notes that a consumer may not finish a vial inside that window, and it addresses the case directly. Discard the vial within twenty-eight days of first use, even if medication remains. FDA says not to keep using it past that point, even where a compounder's instructions allow longer.
FDA also recommends always using a new, sterile needle and syringe for each dose, because reusing them can contaminate the medication. Anything about how to handle your specific product belongs with the instructions it came with and the pharmacy that prepared it.
Measuring a dose is where FDA has seen problems
A vial-and-syringe presentation asks someone to measure. FDA reports it has received adverse event reports, some involving hospitalization, that may be related to dosing errors with compounded injectable semaglutide products.
The agency describes those errors coming from two directions. Patients measuring and self-administering incorrect doses, and in some cases health care professionals miscalculating doses.
FDA also reports adverse event reports that may relate to patients being prescribed compounded semaglutide or tirzepatide in doses beyond what is in the approved drug label. That covers using more product at once, dosing more often, or increasing more quickly.
For a buyer, none of that is a rule about doses. It means a product you measure yourself makes three things worth more. Being taught in person. Having written instructions in the box. And having someone to call when a number on a syringe does not match a number on a page. FDA encourages patients to talk with their health care provider or compounder about how to measure and administer the intended dose.
Read the label as a document, not a sticker
FDA states it is aware of fraudulent compounded semaglutide and tirzepatide marketed in the United States carrying false information on the product label. In some cases the compounding pharmacy named does not exist. In others the label names a real licensed pharmacy that did not compound the product.
That makes a few plain reading checks worth the minute they take. Is there a pharmacy name and an address, and does the address look like a real one? Is the active ingredient printed, and is it what you were told you were buying? Is there a date on it?
FDA's telehealth red flags include spelling errors on the label, incorrect addresses for the pharmacy, and a pharmacy name on the label that you think might be fraudulent. They also include packaging that is broken or damaged, or that lacks instructions for use.
A label that names a pharmacy is a claim you can check against that state's board of pharmacy license database. A label that names nobody has not given you anything to check.
What should have arrived with it
Instructions for use are the first thing to look for, and FDA treats their absence as a red flag rather than an inconvenience.
Then the equipment the form requires. A product you draw yourself needs syringes and needles in the right size, and a sharps container is a practical necessity rather than an accessory.
Then a route to a person. FDA directs anyone with questions about instructions for use or label information to contact the compounder who made the drug or the telehealth platform where it was purchased. Both should be reachable, and it is worth knowing which one answers which question before you need either.
A packing slip or invoice that names the pharmacy is useful to keep. It is the record that ties the box to a company, and it is the thing you will want if a question comes up weeks later.
When something is off
Set it aside rather than using it. FDA's recommendation for a shipment that arrived warm or under-refrigerated is not to use it. The same caution applies to a product that looks different from what you were sent before, or from what was pictured.
Then ask, in writing, and keep the answer. The compounder and the platform are the two parties FDA points consumers to, and a written reply is what makes a replacement conversation straightforward.
FDA asks that unexpected experiences and side effects be reported through its MedWatch program, and it accepts reports of websites that appear to be selling medicine illegally.
Anything about whether a product is safe for you to use is a question for your prescriber or the pharmacy. A comparison of programs cannot answer it, and neither can a photograph on the internet.
Sources
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossRefrigeration and arrived-warm guidance, the 28-day vial recommendation, and a new sterile needle for each dose.
- Compounding and the FDA: Questions and AnswersThat a compounded drug is not FDA-approved and is not reviewed before it is marketed.
Frequently asked questions
Does compounded semaglutide come in a pen or a vial?
Both presentations exist, and which one a program ships is a question to ask before you enroll rather than an assumption to make. FDA states it is aware that compounded GLP-1 medications may be dispensed in vials containing multiple doses for a patient to self-administer. That form asks you to measure each dose, needs syringes and needles, and comes with a discard clock a single-use presentation does not have. The form is a real part of what you are buying, and it rarely appears on a pricing page.
My package arrived warm. Can I still use it?
FDA's recommendation is not to. FDA states that injectable GLP-1 drugs require refrigeration as indicated in their package inserts. It has received complaints of compounded GLP-1 drugs arriving warm, or with inadequate ice packs. Its recommendation is not to use any injectable GLP-1 drug that arrives warm or insufficiently refrigerated, because that can affect the drug's quality. Contact the pharmacy that prepared it and the platform you bought it from, in writing, and keep the reply. Whether a specific product is usable is their question to answer, not a comparison site's.
How long can a multiple-dose vial be used?
FDA generally recommends that vials containing multiple doses of sterile medications be used within twenty-eight days after first use, because the risk of contamination increases after that. It addresses leftover medication directly. Discard the vial within twenty-eight days of first use, even if some remains. FDA says not to continue past that point, even where a compounder's instructions allow a longer period. FDA also recommends a new, sterile needle and syringe for every dose. Your own product's instructions and the pharmacy that prepared it are where to take a question about your specific vial.
What should be printed on the label?
Enough to identify who made it, what is in it, and how to reach someone about it. FDA has reported fraudulent compounded semaglutide and tirzepatide with false label information, including labels naming pharmacies that do not exist and labels naming real pharmacies that did not compound the product. FDA's own red flags include spelling errors on the label, an incorrect pharmacy address, and a pharmacy name you think might be fraudulent. A named pharmacy can be checked against that state's board of pharmacy license database, which is what turns a printed name into a fact.
Are syringes and a sharps container included?
That varies between programs, and it is worth confirming in writing before you enroll. A product you draw yourself needs syringes and needles of the right size for each dose, and used needles need somewhere to go. FDA recommends always using a new, sterile needle and syringe for each dose, since reusing them can contaminate the medication. Whether those arrive with the medication, arrive separately, or are your own errand is part of what a program does and does not include.
The product looks different from my last shipment. Does that matter?
FDA treats it as a warning sign worth acting on. Medicine that looks different from what you received before, or from what was pictured, appears on FDA's list of telehealth red flags. So does packaging that is broken, damaged, or lacking instructions for use. Set it aside instead of using it, then contact the compounder who made it and the platform where you bought it, which are the two parties FDA points consumers to. Keep the reply in writing, and report an unexpected experience or side effect through FDA's MedWatch program.